An analysis of EC patients from the Tumor Cancer Genome Atlas (TCGA) showed that KRAS mutant ECs have increased activation of estrogen signaling, by means of increased RAS/MAPK pathway signaling. This evidence concerns the gene KRAS and neoplasm.